THE RISK OF POISONING FROM THE USE OF OZEMPIC (SEMAGLUTIDE) IN NON-DIABETIC PATIENTS

• Autor(a) principal: Sagratzki , Rebecka Marques Gomes
• Data de Publicação: 2023
• Outros Autores: Silva, Suellen Souza da, Mascarenhas , Auro Régio Rocha, Póvoa , Carolline Sabino, Souza , Eduarda Martins, Silva , Jonathan Tavares Da, Santos , Pedro Henrique Queiroz Dos, Silva , Vinicios Batista Monteiro, Paiva , Maykon Jhuly Martins de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/501
• topic: Ozempic, Semaglutida, diabetes, emagrecimento e intoxicação medicamentosa; Ozempic, Semaglutide, diabetes, weight loss and drug intoxication; Ozempic, Semaglutida, diabetes, pérdida de peso e intoxicación por fármacos

Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist originally used in the treatment of type 2 diabetes, has generated interest as a new approach to reducing obesity, as studies point to a high efficacy in reducing systolic blood pressure in obese patients, weight loss and a slight reduction in diastolic blood pressure. The objective of this systematic review was to find out what are the possible adverse effects caused by Semaglutide in patients who do not have DM2, since there are still few studies regarding the toxicity of the drug in non-diabetic patients. According to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines, the databases of the Pubmed and Scielo libraries were systematically used for all studies in this review. Meta-analyses, systematic reviews and randomized clinical trials that addressed the topic between 2012 and 2023 were included. Although the analyzed studies demonstrated efficacy in the use of semaglutide, mainly in non-diabetic obese patients, adverse effects were observed, mainly gastrointestinal, among them there are vomiting, nausea, diarrhea and abdominal pain, mild to moderate, in all analyzed studies, and should be taken into account before using and indicating the drug. It is also necessary for health professionals to follow up more closely and take greater care with patients who already have some type of comorbidity and who may be affected by the adverse effects of the medication. More long-term studies on the use of Ozempic in non-diabetic patients are still needed to be more certain about its toxicity.